Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Bendamustine, Gemcitabine and Vinorelbine (BEGEV) Chemotherapeutic Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma

NCT07450508 is registered in ClinicalTrials.gov with Cairo University as lead sponsor.

NCT NCT07450508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07450508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Bendamustine, Gemcitabine and Vinorelbine (BEGEV) Chemotherapeutic Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma
Lead sponsor
Cairo University
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2024
Completion date
February 1, 2026
Enrollment
88 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma relapsed